title: Pronostic factors of synchronous brain metastases from lung cancer.
abstract: BACKGROUND
  The prognosis of brain metastases (BM) from lung cancer is poor. The management of lung cancer with BM is not clear. This retrospective study attempts to determine their prognostic factors, and to better define the role of different treatments.
  
  
  METHODS
  We reviewed the clinical characteristics of 271 consecutive patients with synchronous brain metastases (SBM) from lung cancer (small-cell lung cancers and non-small-cell lung cancers), collected between January 1985 and May 1993. Data were available for all patients as well as follow-up information on all patients through to death. Patients had all undergone heterogeneous treatments. Each physician had chosen the appropriate treatment after collegiate discussion. Survival curves were compared using the log-rank test in univariate analysis, and Cox's Regression model in multivariate analysis. Statistical significance was defined as P<0.05.
  
  
  RESULTS
  249 patients were assessable. Treatments included: neurosurgical resection in 56 cases, brain irradiation in 87 cases, and chemotherapy in 126 cases. Median overall survival time from the date of histological diagnosis of SBM was 103 days (range, 1-1699). In multivariate analysis, prognostic factors for longer overall survival times were: absence of adrenal metastases (P=0.007), neurosurgical resection (P=0.028), chemotherapy (P=0.032) and brain irradiation (P=0.008). Moreover, risk factors of intracranial hypertension as cause of death were number of SBM and absence of neurosurgical resection.
  
  
  CONCLUSIONS
  These results and others suggest that patients with SBM from lung cancer be considered for carcinologic treatment, and not only for best supportive care. However, further studies are necessary to evaluate quality of life with or without carcinologic treatment.
authors.affiliation: Oscar Lambret Cancer Center, 3, rue Frederic Combemale, B.P. 307, 59020 Lille, France.
authors.forename: N
authors.initials: N
authors.lastname: Penel
authors.forename: A
authors.initials: A
authors.lastname: Brichet
authors.forename: B
authors.initials: B
authors.lastname: Prevost
authors.forename: A
authors.initials: A
authors.lastname: Duhamel
authors.forename: R
authors.initials: R
authors.lastname: Assaker
authors.forename: F
authors.initials: F
authors.lastname: Dubois
authors.forename: J J
authors.initials: JJ
authors.lastname: Lafitte
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000175:diagnosis / Q000556:secondary* / Q000628:therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000556:secondary* / Q000628:therapy; D016371:Cranial Irradiation; D005260:Female; D006801:Humans; D017567:Karnofsky Performance Status; D015993:Life Tables; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome